Cognition Therapeutics (NASDAQ:CGTX) Earns “Buy” Rating from Chardan Capital

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report released on Friday,Benzinga reports. They presently have a $4.00 price objective on the stock. Chardan Capital’s price objective points to a potential upside of 447.87% from the company’s previous close.

A number of other research firms also recently commented on CGTX. upgraded Cognition Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $3.33.

Cognition Therapeutics Price Performance

Shares of CGTX stock opened at $0.73 on Friday. The company has a market capitalization of $64.45 million, a PE ratio of -2.21 and a beta of 1.25. The firm’s 50-day moving average is $1.13 and its two-hundred day moving average is $1.43. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04. Sell-side analysts forecast that Cognition Therapeutics will post -0.8 EPS for the current year.

Hedge Funds Weigh In On Cognition Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. lifted its position in shares of Cognition Therapeutics by 34.7% during the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock worth $40,000 after purchasing an additional 7,641 shares during the last quarter. Bryn Mawr Trust Advisors LLC increased its holdings in Cognition Therapeutics by 69.1% in the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after buying an additional 16,129 shares during the last quarter. Jones Financial Companies Lllp acquired a new stake in Cognition Therapeutics in the third quarter valued at $25,000. Essex Financial Services Inc. purchased a new stake in Cognition Therapeutics during the 4th quarter worth about $27,000. Finally, Gamco Investors INC. ET AL purchased a new stake in Cognition Therapeutics during the 3rd quarter worth about $27,000. 43.35% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Cognition Therapeutics

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Q4 / year‑end 2025 results: CGTX reported adjusted results that beat consensus — EPS of ($0.02) vs. ($0.06) expected — signaling a smaller loss than anticipated. MarketBeat Earnings
• Positive Sentiment: Clinical development progress: Management reiterated advancement of zervimesine for DLB psychosis and expects a meeting with the FDA Division of Psychiatry by mid‑2026 — a concrete regulatory milestone that could define next‑step study requirements or timing. GlobeNewswire Release
• Positive Sentiment: Analyst support: Chardan Capital reaffirmed a “buy” rating and set a $4.00 price target, implying substantial upside versus current levels — a bullish endorsement that could attract longer‑term investors. Benzinga
• Neutral Sentiment: Additional disclosures and call materials: The company published its year‑end 2025 financial report and hosted a management call; full transcripts and summaries are available for investors who want details on pipeline timing, cash position, and management commentary. Earnings Call Transcript
• Negative Sentiment: Heavy selling pressure and volatility: the stock is down sharply on much higher volume than average (several million shares traded vs. an ~943k average), indicating large-scale selling or short‑term profit taking. That flow, combined with typical biotech risks (limited near‑term revenue, potential financing/dilution questions), likely overwhelmed the positive news and pushed the share price lower. MarketBeat Quote

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.